Blog
Peptide research, protocols, and community insights.
The Safety Net Under Compounded Drugs Has Some Large Holes
A study in the Journal of the American Pharmacists Association looked at newly registered compoundin…
Eighteen Vials of Counterfeit Retatrutide Went to a Lab. One Matched Its Label.
An Australian laboratory tested 18 counterfeit retatrutide samples. Only one contained what the labe…
Sterile Is Not the Same as Safe: A Recall Worth Understanding
A compounding pharmacy recalled three lots of injectable peptide over high endotoxin levels after pa…
A Peptide Seller Got Six Years, and the Lab Certificates Were Forged
A peptide company owner was sentenced to 70 months in federal prison for selling unapproved drugs wi…
Three Gut Peptides, Ranked by Evidence Instead of Hype
BPC-157, KPV, and larazotide are the three peptides sold hardest for gut problems. Ranked by how muc…
The One Peptide the FDA Panel Turned Down
Seven peptides went before the FDA advisory committee in July. Six were recommended for compounding.…
The Obesity Nobody Chose, and the First Drug That Treats It
Some people develop relentless hunger after a brain tumor damages the part of the brain that control…
The Vial Problem: Why Compounded GLP-1s Keep Causing Overdoses
US regulators have logged more than 1,700 adverse event reports tied to compounded semaglutide and t…
The Biggest Review of Skin Peptides Yet, and What It Found
Researchers pooled 19 randomized trials covering 1,341 people to ask whether peptides actually do an…
A Weight Loss Drug Just Cut Knee Pain by 75 Percent
Retatrutide produced 28.7 percent average weight loss in its first Phase 3 obesity trial, the highes…
After GLP-1: Why Every Big Drugmaker Is Now Chasing Amylin
Novo Nordisk, Eli Lilly, Roche, and Amgen are all running trials on a second appetite hormone called…
An FDA Panel Just Voted to Let Pharmacies Make Six Peptides
On July 23, 2026, an FDA advisory committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, Semax,…
The First GLP-1 Pill You Can Take Any Time: Lilly's Foundayo Is Here
On April 1, 2026, the FDA approved Foundayo, a daily weight loss pill from Eli Lilly. It is the firs…
BPC-157 and TB-500: Why the Healing Hype Is Running Ahead of the Proof
BPC-157 and TB-500 are pitched online as near-magic fixes for injured tendons, joints, and guts. But…
Telomeres, Sleep, and Hype: A Plain Look at Longevity Peptides Like Epitalon
Epitalon, MOTS-c, and NAD+ get sold online as an anti-aging stack that slows the clock. The biology…
Five Big Drug Results in Four Days: What the ADA 2026 Meeting Told Us
The American Diabetes Association meeting ran from June 5 to 8 in New Orleans, and it was a packed w…
A Lab-Tested BPC-157 Just Launched: What It Says About the Research Peptide Market
On June 9, 2026, Koi Peptides released a BPC-157 reference compound for lab use, with a certificate…
Retatrutide Goes the Distance: The Full Phase 3 Diabetes Data Is Here
At the ADA 2026 meeting, Eli Lilly shared the first full Phase 3 results for retatrutide in people w…
Once a Month Instead of Once a Week: Inside Pfizer's New GLP-1 Results
At the ADA meeting on June 6, Pfizer showed off VESPER-3 results for a long-acting GLP-1 shot that o…
Hims and Hers Shares Jump 49% in a Week on Peptide Pipeline and Novo Nordisk Deal
Hims and Hers stock surged 49% over five sessions as investors reacted to renewed FDA interest in pe…